Veracyte says OPTIMA trial shows Prosigna test helps 68% of high-risk breast cancer patients avoid chemotherapy

Veracyte, Inc.

Veracyte, Inc.

VCYT

0.00
  • Veracyte announced OPTIMA Phase III trial results for its Prosigna breast cancer test, with findings set for presentation May 30 at ASCO 2026.
  • The study found the test can guide treatment choices so many clinically high-risk early-stage patients can skip chemotherapy without worsening outcomes.
  • Results support wider adoption of Prosigna to reduce chemotherapy use in hormone receptor-positive, HER2-negative breast cancer, including node-positive disease.
  • Veracyte framed the data as the strongest prospective evidence for Prosigna in predicting chemotherapy benefit, strengthening its competitive position in genomic testing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260528130751) on May 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.